Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Current Opinion in Oncology|August 24, 2022
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy resultsAlberto Picca, Gaetano FinocchiaroPresse Medicale (Paris, France : 1983)|March 16, 2026
Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated reviewAlberto Picca, Dimitri PsimarasCurrent Opinion in Oncology|August 28, 2020
Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practiceGiulia Berzero, Alberto Picca, Dimitri PsimarasTherapeutic Advances in Neurological Disorders|February 7, 2018
Current therapeutic approaches to diffuse grade II and III gliomasAlberto Picca, Giulia Berzero, Marc SansonCurrent Opinion in Neurology|September 22, 2018
Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomasAlberto Picca, Anna L Di Stefano, Marc SansonExpert Review of Neurotherapeutics|November 20, 2023
Advances in molecular and imaging biomarkers in lower-grade gliomasAlberto Picca, Francesco Bruno, Lucia Nichelli, et al.Expert Review of Molecular Diagnostics|November 15, 2018
The clinical use of IDH1 and IDH2 mutations in gliomasAlberto Picca, Giulia Berzero, Anna Luisa Di Stefano, et al.Clinical Nuclear Medicine|February 13, 2026
18F-DOPA PET Silence in High-grade Glioma Subtype F: A Distinct Metabolic PhenotypeChloé Quéré, Franck Bielle, Alberto Picca, et al.Cancers|December 9, 2023
Diffuse Gliomas with FGFR3-TACC3 Fusions: Oncogenic Mechanisms, Hallmarks, and Therapeutic PerspectivesAlberto Picca, Giulio Sansone, Orazio Santo Santonocito, et al.Neurology(R) Neuroimmunology & Neuroinflammation|September 9, 2021
Anti-Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint InhibitorsAlberto Picca, Nefeli Valyraki, Cristina Birzu, et al.Pageof 4